Sickle Cell Disease

Limited Treatment Options

First described more than 100 years ago, this disease shortens lives and causes patients to live with near constant pain to almost 300,000 children worldwide.

Read More

Clinical Development

Introducing IMR-687

IMR-687 was identified and selected specifically to treat patients with sickle cell disease.

Read More
Imara Spotlight

Trying to Get Ahead of Sickle Cell Disease

Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating white blood cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat individuals living with sickle cell disease. IMR-687 targets both the red blood cell and white blood cell to treat the underlying cause of pain and organ damage. Imara is working with patients, their families and clinicians taking care of people with sickle cell disease to advance IMR-687 into human clinical studies.

Learn More